GlobeNewswire Inc.··Bioversys AgBioVersys to Showcase Late-Stage Antibiotic Pipeline at ESCMID 2026
BioVersys will present Phase 3 data for BV100 and collaborate data for BV500 at ESCMID 2026, advancing its antibiotic-resistant infection pipeline.
SGIOYPhase 3 clinical trialantimicrobial resistance